NovoCure Ltd — Director's Dealing 2018

Aug 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2018-07-31

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-31	Options to Buy Ordinary Shares	$34.00	A	20458	Acquired	2028-07-30	Ordinary Shares (20458)	Direct
2018-07-31	Restricted Stock Unit	$	A	11152	Acquired		Ordinary Shares (11152)	Direct

Footnotes

F1: Options to buy 20,458 ordinary shares will vest and become exercisable in equal installments on each of July 31, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.

F2: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.

F3: One-third of these restricted stock units are scheduled to vest on each of July 31, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates.